OP15L
Anti-c-ErbB2/c-Neu (Ab-3) Mouse mAb (3B5)
lyophilized, clone 3B5, Calbiochem®
Synonyme(s) :
Anti-HER2, Anti-Neu, Anti-ErbB2, Anti-Erythroblastosis Virus, Anti-Human Epidermal Growth Factor
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
Nomenclature NACRES :
NA.43
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified antibody
Type de produit anticorps
primary antibodies
Clone
3B5, monoclonal
Forme
lyophilized
Ne contient pas
preservative
Espèces réactives
mouse, human
Fabricant/nom de marque
Calbiochem®
Conditions de stockage
OK to freeze
Isotype
IgG1
Conditions d'expédition
ambient
Température de stockage
2-8°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... ERBB2(2064)
Description générale
Anti-c-ErbB2/c-Neu (Ab-3), mouse monoclonal, clone 3B5, recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells. It is validated for WB, IF, IP, and IHC on frozen and paraffin sections.
Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing with Sp2/0.Ag14 cells (see application references). Recognizes the ~185 kDa c-ErbB2/c-Neu protein.
Recognizes the ~185 kDa c-ErbB2/c-Neu protein in HEK293 cells.
Immunogène
Human
a synthetic peptide (TAENPEYLGLDVPV) corresponding to amino acids 1242-1255 from the C-terminal domain of human c-ErbB2/c-Neu
Application
Frozen Sections (2.5 g/ml)
Immunoblotting (2.5 g/ml, see application references)
Immunofluorescence (2.5 g/ml)
Immunoprecipitation (1 g per sample, see application references)
Paraffin Sections (2.5 g/ml, pressure cooker pre-treatment required, see application references)
Avertissement
Toxicity: Standard Handling (A)
Forme physique
Lyophilized from 20 mM ammonium bicarbonate Buffer, 100 µg FAF-BSA.
Reconstitution
Reconstitue the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing for at least 2 h. Store at 4°C until reconstituted, then store in aliquots at -20°C or at 4°C with 0.1% azide. Freezing of aliquots is best for long term storage of reconstituted product; repetitive freezing and thawing should be avoided.
Remarque sur l'analyse
Negative Control
HepG2 cells or normal skin
HepG2 cells or normal skin
Positive Control
SK-BR-3 cells or breast carcinoma tissue
SK-BR-3 cells or breast carcinoma tissue
Autres remarques
For paraffin sections, we recommend pre-treating with a pressure cooker, but trypsin and heat will also work well. Including 0.05% saponin during staining of paraffin sections may help reduce background. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribriform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.
Mamcs, J.R., et al. 1994. Ann. Surg.219, 332.
Tetu, B., et al. 1994. Cancer73, 2359.
DiFiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Tetu, B., et al. 1994. Cancer73, 2359.
DiFiore, P.P., et al. 1987. Science237, 178.
Slamon, D.J., et al. 1987. Science235, 177.
Varley, J.M., et al. 1987. Oncogene1, 423.
Bargmann, C.I., et al. 1986. Nature319, 226.
Yamamoto, T., et al. 1986. Nature319, 230.
Blick, M., et al. 1984. Blood64, 1234.
Schwab, M., et al. 1984. Cold Spring Harbor Laboratory2, 215.
Informations légales
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 1
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
B Spänkuch et al.
Oncogene, 26(39), 5793-5807 (2007-03-21)
Commonly used drugs for the treatment of breast cancer patients like paclitaxel and Herceptin often show severe side effects or induce resistance in clinical settings. Thus, we analysed a combination of Plk1 (polo-like kinase 1)-specific small interfering RNAs (siRNAs), a
Karin Haim et al.
Neoplasia (New York, N.Y.), 13(3), 230-243 (2011-03-11)
The tumor microenvironment contains multiple cancer-supporting factors, whose joint activities promote malignancy. Here, we show that epidermal growth factor (EGF) and estrogen upregulate in an additive manner the transcription and the secretion of the angiogenic chemokine CXCL8 (interleukin 8 [IL-8])
Soo-Hyun Kim et al.
Disease models & mechanisms, 11(7) (2018-05-23)
Breast cancer brain metastases remain largely incurable. Although several mouse models have been developed to investigate the genes and mechanisms regulating breast cancer brain metastasis, these models often lack clinical relevance since they require the use of immunocompromised mice and/or
Marianne K Kim et al.
BMC cancer, 16, 678-678 (2016-08-26)
shRNA-mediated lethality screening is a useful tool to identify essential targets in cancer biology. Ovarian cancer (OC) is extremely heterogeneous and most cases are advanced stages at diagnosis. OC has a high response rate initially, but becomes resistant to standard
Björn Kruspig et al.
Science translational medicine, 10(446) (2018-06-22)
KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in KRAS are thought to confer independence from upstream signaling; however
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique